Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-6194 phase 2 study in adults with non-segmental vitiligo
NL-OMON59587Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of PT101 in Vitiligo, sponsored by Merck & Co. Primary endpoints: Change from baseline in Facial Vitiligo Area Scoring Index at Week 24, Number of participants who experience an adverse event and 1 more. Started Feb 2024; status: completed.
02
Drugs
PT101
03
Conditions
Vitiligo
Beyond the preview
Go deeper on NL-OMON59587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59587.